Jump to content

Cristina Pearse

Add links
From Wikipedia, the free encyclopedia

Cristina Pearse (age 51) is a US-based complex post-traumatic stress disorder survivor[1][2] and women's trauma recovery advocate,[3][4] living in Boulder, Colorado, United States.[3]

Cristina Pearse
Born
Boulder, Colorado, United States
CitizenshipU.S
OccupationWomen's trauma recovery advocate

Early life and professional career

[edit]

When Cristina Pearse was a young girl, she was sexually assaulted throughout an adverse childhood.[5] With an ACE score of 9,[6][7] Cristina later developed PTSD.[8][9][10] She said that numerous psychiatric prescriptions had been given to her over the years, and she had even made an attempt at suicide as a negative side effect of one medication.[3]

On June 4, 2024, she addressed the FDA advisory committee in support of approval of MDMA-assisted therapy,[3][11] stating that her complex PTSD symptoms had essentially abated after receiving MDMA-assisted (midomafetamine) therapy during the phase 3 drug trial.[1][4][12]

She asked the committee, "How many more people need to die before we approve an effective therapy?"[13]

She is the CEO and founder of women's trauma recovery Protea Foundation,[1] with its mission to increase awareness of the prevalence of unreported sexual assault and its impact on women, improve access to effective therapies for C-PTSD and PTSD,[14][15][16] especially for underrepresented populations, and teach a resilience skills program, Navigating Trauma River, to teach youth how to be more resilient through childhood adversity.[9][17][18][19][20]

Pearse is one of about 100 people who were included in the groundbreaking trial.[21][22]

References

[edit]
  1. ^ a b c "Illegal Ecstasy Takes Step Toward Becoming Legal Drug for PTSD". Bloomberg.com. 2024-05-30. Retrieved 2024-07-16.
  2. ^ Lewis Herman, Judith (1992). "Complex PTSD: A syndrome in survivors of prolonged and repeated trauma". Journal of Traumatic Stress. 5 (3): 377–391. doi:10.1002/jts.2490050305. ISSN 0894-9867.
  3. ^ a b c d Jacobs, Andrew (2024-06-04). "F.D.A. Panel Rejects MDMA-Aided Therapy for PTSD". The New York Times. ISSN 0362-4331. Retrieved 2024-07-25.
  4. ^ a b "Ketamine Insights". Ketamine Insights. Retrieved 2024-07-25.
  5. ^ "Education and Labor Committee. (2019). Written statement of Dr. Nadine Burke Harris. U.S. House Committee on Education and Labor" (PDF).
  6. ^ Felitti, Vincent J; Anda, Robert F; Nordenberg, Dale; Williamson, David F; Spitz, Alison M; Edwards, Valerie; Koss, Mary P; Marks, James S (1998). "Relationship of Childhood Abuse and Household Dysfunction to Many of the Leading Causes of Death in Adults". American Journal of Preventive Medicine. 14 (4): 245–258. doi:10.1016/s0749-3797(98)00017-8. ISSN 0749-3797. PMID 9635069.
  7. ^ Crouch, Elizabeth; Probst, Janice C.; Radcliff, Elizabeth; Bennett, Kevin J.; McKinney, Selina Hunt (2019-06-01). "Prevalence of adverse childhood experiences (ACEs) among US children". Child Abuse & Neglect. 92: 209–218. doi:10.1016/j.chiabu.2019.04.010. ISSN 0145-2134. PMID 31003066.
  8. ^ Redmon, Jeremy. "Emory researchers studying psychedelic-assisted treatment for PTSD". The Atlanta Journal-Constitution. ISSN 1539-7459. Retrieved 2024-07-25.
  9. ^ a b Goldenson, Julie; Kitollari, Iljona; Lehman, Francesca (2021-03-01). "The Relationship Between ACEs, Trauma-Related Psychopathology and Resilience in Vulnerable Youth: Implications for Screening and Treatment". Journal of Child & Adolescent Trauma. 14 (1): 151–160. doi:10.1007/s40653-020-00308-y. ISSN 1936-153X. PMC 7900283. PMID 33708289.
  10. ^ Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association. 2013-05-22. doi:10.1176/appi.books.9780890425596. ISBN 978-0-89042-555-8.
  11. ^ Nuwer, Rachel. "FDA's Rejection of MDMA Psychotherapy for Trauma Draws Criticism from Psychedelic Experts". Scientific American. Retrieved 2024-08-16.
  12. ^ Mitchell, Jennifer M.; Ot’alora G., Marcela; van der Kolk, Bessel; Shannon, Scott; Bogenschutz, Michael; Gelfand, Yevgeniy; Paleos, Casey; Nicholas, Christopher R.; Quevedo, Sylvestre; Balliett, Brooke; Hamilton, Scott; Mithoefer, Michael; Kleiman, Sarah; Parker-Guilbert, Kelly; Tzarfaty, Keren (October 2023). "MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial". Nature Medicine. 29 (10): 2473–2480. doi:10.1038/s41591-023-02565-4. ISSN 1546-170X. PMC 10579091. PMID 37709999.
  13. ^ Musk, Christiana (2024-08-07). "There Are No Good Treatments for PTSD. MDMA Can Change That". Time. Retrieved 2024-08-15.
  14. ^ "Risk and Protective Factors". Center for Disease Control. 2024-07-11. Retrieved 2024-07-25.
  15. ^ Frewen, Paul; Zhu, Jenney; Lanius, Ruth (2019-12-31). "Lifetime traumatic stressors and adverse childhood experiences uniquely predict concurrent PTSD, complex PTSD, and dissociative subtype of PTSD symptoms whereas recent adult non-traumatic stressors do not: results from an online survey study". European Journal of Psychotraumatology. 10 (1). doi:10.1080/20008198.2019.1606625. ISSN 2000-8066. PMC 6507912. PMID 31105905.
  16. ^ Ungar, Michael T. (2001). "Constructing Narratives of Resilience with High-Risk Youth". Journal of Systemic Therapies. 20 (2): 58–73. doi:10.1521/jsyt.20.2.58.23040. ISSN 1195-4396.
  17. ^ Leppin, Aaron L.; Gionfriddo, Michael R.; Sood, Amit; Montori, Victor M.; Erwin, Patricia J.; Zeballos-Palacios, Claudia; Bora, Pavithra R.; Dulohery, Megan M.; Brito, Juan Pablo; Boehmer, Kasey R.; Tilburt, Jon C. (2014-03-06). "The efficacy of resilience training programs: a systematic review protocol". Systematic Reviews. 3 (1): 20. doi:10.1186/2046-4053-3-20. ISSN 2046-4053. PMC 3946765. PMID 24602236.
  18. ^ Luthar, Suniya S.; Cicchetti, Dante; Becker, Bronwyn (May 2000). "The Construct of Resilience: A Critical Evaluation and Guidelines for Future Work". Child Development. 71 (3): 543–562. doi:10.1111/1467-8624.00164. ISSN 0009-3920. PMC 1885202. PMID 10953923.
  19. ^ Rog, Debra J.; Reidy, Mary Clare; Manian, Nanmathi; Daley, Tamara C.; Lieberman, Leslie (February 2021). "Opportunities for psychologists to enact community change through adverse childhood experiences, trauma, and resilience networks". American Psychologist. 76 (2): 379–390. doi:10.1037/amp0000778. ISSN 1935-990X. PMID 33734802.
  20. ^ Steinhardt, Mary; Dolbier, Christyn (January 2008). "Evaluation of a Resilience Intervention to Enhance Coping Strategies and Protective Factors and Decrease Symptomatology". Journal of American College Health. 56 (4): 445–453. doi:10.3200/JACH.56.44.445-454. ISSN 0744-8481. PMID 18316290.
  21. ^ "Food and Drug Adminsitration Center for Drug Evaluations and Research".
  22. ^ Mitchell, Jennifer M.; Ot’alora G., Marcela; van der Kolk, Bessel; Shannon, Scott; Bogenschutz, Michael; Gelfand, Yevgeniy; Paleos, Casey; Nicholas, Christopher R.; Quevedo, Sylvestre; Balliett, Brooke; Hamilton, Scott; Mithoefer, Michael; Kleiman, Sarah; Parker-Guilbert, Kelly; Tzarfaty, Keren (October 2023). "MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial". Nature Medicine. 29 (10): 2473–2480. doi:10.1038/s41591-023-02565-4. ISSN 1546-170X. PMC 10579091.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Cristina_Pearse&oldid=1242566404"